Since diverse signal transduction pathways control tumor resistance to antineoplastic agents, we hypothesized that, unlikely the MAPK inhibitor PD98059, a PI3K-Akt pathway inhibitor could decrease cell survival in the presence of matuzumab. Here, PIK3CA is linked to neoplasm.